Acasti Pharma Inc is a biopharmaceutical company operating in Canada. It focuses on the research, development, and commercialization of prescription drugs using omega-3 fatty acids derived from krill oil. The key product candidate of the company, CaPre is developed for the treatment of severe hypertriglyceridemia, which is a condition characterized by abnormally high levels of triglycerides in the bloodstream. The company operates through the single segment being Development and commercialization of prescription drugs.